inews.co.uk on MSN5d
At 63, my prostate cancer is terminal – one test could have changed everythingKeven Williams says a private health check-up did not detect his cancer. By the time he was diagnosed two years later, it had ...
One test could have prevented terminal prostate cancer, says patient - Research has shown that the use of the PSA test varies ...
Androgen receptor non-canonical domain binding degrader for treatment of relapsed, refractory castration-resistant prostate cancer: K. Sadasivan Pillai Wednesday, March 5, 2025, 0 ...
The first patient has been dosed in a first-in-human clinical trial evaluating HLD-0915 for metastatic castration-resistant ...
In a live event, Ganesh V. Raj, MD, PhD, discussed the landscape of metastatic hormone-sensitive prostate cancer considering ...
(UroToday.com) The 2025 APCCC Diagnostics annual meeting featured a session on how to monitor metastatic prostate cancer and ...
Novartis Pharmaceuticals Canada Inc. (Novartis) welcomes the Government of Alberta's decision to publicly reimburse Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan injection) for eligible patients ...
On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with ...
GlobalData on MSN11d
Eikon raises almost $351m to advance cancer candidates through the clinicEikon’s lead candidate EIK1001 is being investigated for melanoma in combination with MSD’s Keytruda in a Phase III trial.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback